Acta Scientific Microbiology (ISSN: 2581-3226)

Editorial Volume 6 Issue 5

Patients with Lung Cancer Receiving Immune Checkpoint Inhibitors: Safety and Immunogenicity of mRNA-COVID-19 Vaccination

Attapon Cheepsattayakorn1,2*, Ruangrong Cheepsattayakorn3 and Porntep Siriwanarangsun1

1Faculty of Medicine, Western University, Pathumtani Province, Thailand

210th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

3Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: March 03, 2023; Published: April 01, 2023

Currently, in cancer or lung-cancer patients, immune checkpoint inhibitors (ICIs), such as anti-CTLA-4, anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1) antibodies, etc. are widely prescribed as single agent or in combination with other anticancer-   treatment modalities [1]. Due to immune-associated adverse events (iaAEs), these ICIs can facilitate antitumor effects, such as interstitial pneumonitis, endocrine-gland-disorders-associated abnormal hormone secretion [2] that can be caused and aggravated by mRNA-based-COVID-19 vaccines (Figure 1) [1,3].

References

  1. Hibino M., et al. “Safety and immunogenicity of mRNA vaccines against severe acute respiratory syndrome coronavirus 2 in patients with lung cancer receiving immune checkpoint inhibitors: a multicenter observational study in Japan”. Journal of Thoracic Oncology8 (2022): 1002-1013.
  2. Brahmer JR., et al. “Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology Clinical Practice Guideline”. Journal of Clinical Oncology 36 (2018): 1714-1768.
  3. Desage AL., et al. “Vaccination and immune checkpoint inhibitors : does vaccination increase the risk of immune-related adverse events?: a systematic review of literature”. American Journal of Clinical Oncology 44 (2021): 109-113.

Citation

Citation: Attapon Cheepsattayakorn., et al. “Patients with Lung Cancer Receiving Immune Checkpoint Inhibitors: Safety and Immunogenicity of mRNA-COVID-19 Vaccination". Acta Scientific Microbiology 6.5 (2023): 01-02.

Copyright

Copyright: © 2022 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days

Indexed In






News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US